An effective nanoparticle-based drug delivery platform holds great promise for non-invasive
cancer therapy. This study explores the
breast tumor regression in vivo by synergistic photothermal-
chemotherapy based on liposomal nanocomplex (
folic acid-
gold nanorods-anticancer drug-
liposome). The proposed liposomal nanocomplex can enhance the
tumor targeting by functionalizing
folic acid (FA) molecules on the surface of
liposome that encapsulates both
gold nanorods (AuNRs) and the
doxorubicin (DOX) to combine the
photothermal therapy and the
chemotherapy, respectively. Herein, 7-nm
gold nanorods were fabricated and co-encapsulated with DOX into nanoliposomes functionalized with FA, with an average diameter of 154 nm, for active targeting to the
cancer cells. The experimental results showed that the FA targeting
liposomes had better cellular uptake than the non-targeting
liposomes (AuNRs-DOX-LPs). Especially, upon 5 min exposure to near infrared (NIR) irradiation (808 nm) triggered DOX release could be achieved to 46.38% in 60 min at pH 5.5. In addition, in vitro cell proliferation assays indicated that, with synergistic photothermal-
chemotherapy, the targeting
liposomes could significantly enhance the toxicity towards the
cancer cells with the IC50 value of 1.90 ± 0.12 μg mL-1. Furthermore, in vivo experiments on the
breast tumor-bearing mice showed that the targeting
liposomes could effectively inhibit the growth of the
tumors using the combined strategy.